By the WPG Research Team · Last verified: May 15, 2026 · Next scheduled review: August 2026 (quarterly cadence for FDA label changes; monthly check for new GLP-1 approvals) · Every washout window on this page is sourced to a current FDA prescribing information document, an ex-US regulator (UK MHRA or Canadian product monograph), or a named peer-reviewed study.
GLP‑1 Washout Period Before Pregnancy: How Long to Stop Each Drug Before Trying to Conceive (2026)
Last updated: · Last verified: May 15, 2026
If you're looking up the GLP‑1 washout period before pregnancy because you're on Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, Foundayo, or another GLP‑1 medication, here is the bottom line.
Stop semaglutide (Wegovy, Wegovy HD, Wegovy tablets, Ozempic, Rybelsus) at least 2 months before you start trying. That is the FDA-label rule. For tirzepatide (Mounjaro, Zepbound), the UK MHRA and Canadian product monograph say at least 1 month before a planned pregnancy — the US labels do not give a numeric window. Liraglutide (Saxenda, Victoza) clears in about 3 days. Foundayo (orforglipron), the new oral GLP‑1 approved in April 2026, has a 29–49 hour half-life (~6–10 days to 99% clearance) but no numeric preconception window in its label — the stop date is a prescriber call.
Got a positive pregnancy test while still on a GLP‑1?
Don't take another dose. Call your prescriber or OB-GYN the same day. If you take the GLP‑1 for Type 2 diabetes, don't stop or change anything else in your glucose plan on your own — ask what to switch to. Enroll in the manufacturer's pregnancy exposure registry. The full playbook is in the What to do if you're already pregnant section below.
Fast answer: GLP‑1 washout period before pregnancy by drug
| Your drug (active ingredient) | Stop how long before trying? | Source |
|---|---|---|
| Wegovy / Wegovy HD / Wegovy tablets / Ozempic / Rybelsus (semaglutide) | At least 2 months | US FDA label (long half-life) |
| Mounjaro / Zepbound (tirzepatide) | At least 1 month | UK MHRA + Canadian product monograph (US label is silent on a numeric window) |
| Saxenda (liraglutide, weight loss) | Days, not months — confirm with prescriber | US FDA label (discontinue when pregnancy recognized; weight loss not recommended in pregnancy) |
| Victoza (liraglutide, Type 2 diabetes) | Days, not months — confirm with prescriber and a diabetes bridge plan | US FDA label (use only if benefit justifies risk) |
| Trulicity (dulaglutide) | At least 1 month | Canadian product monograph (US label is silent on a numeric window) |
| Foundayo (orforglipron) | No numeric label rule — half-life math gives ~6–10 days; confirm with prescriber | US FDA label + pharmacokinetic math |
| Bydureon BCise (exenatide ER) | About 12 weeks | UK FSRH/CoSRH contraception guidance |
The 3 dates you need on your calendar
Before anything else, write these three dates down. Everything else on this page exists to help you fill them in.
- 1
Last dose date
The day of your last injection or pill. The washout clock starts here, not the day your next dose would have been due.
- 2
Contraception-through date
The day you can stop using birth control. For most GLP-1s this is the same as your earliest-try date. For tirzepatide, there is a second clock that runs separately (more below).
- 3
Earliest try or transfer date
The day your specific drug's washout window ends. Pull this from the table above, then confirm with your prescriber.
Three lines. That's the whole plan. Everything that follows is the why.
How long should I stop my GLP‑1 before getting pregnant?
Answer capsule
Stop your GLP‑1 at least as long before trying to conceive as your specific drug's FDA label or ex-US regulator guidance states. For semaglutide products the US FDA label requires at least 2 months. For tirzepatide the US label does not state a numeric preconception window — the verified minimums come from the UK MHRA and Canadian product monographs, both at 1 month. Liraglutide clears in about 3 days. Foundayo (orforglipron) clears in 6–10 days by pharmacokinetic math. Your prescriber's specific number overrides everything else on this page.
Table 1: GLP‑1 preconception washout — by source, with half-life and clearance
| Drug (brand) | Active ingredient | US FDA label (preconception) | Ex-US regulator window | Half-life | ~99% cleared (5 half-lives) |
|---|---|---|---|---|---|
| Wegovy injection / Wegovy HD | semaglutide | Discontinue at least 2 months before a planned pregnancy | UK MHRA: 2 months | ~7 days (165 hours) | ~35 days |
| Wegovy tablets | semaglutide (oral) | Same 2-month preconception rule as Wegovy injection | UK MHRA: 2 months | ~7 days | ~35 days |
| Ozempic | semaglutide | Discontinue at least 2 months before a planned pregnancy | UK MHRA: 2 months | ~7 days | ~35 days |
| Rybelsus | semaglutide (oral) | Same 2-month preconception rule | UK MHRA: 2 months | ~7 days | ~35 days |
| Mounjaro | tirzepatide | Discontinue when pregnancy is recognized; no numeric preconception window | UK MHRA: at least 1 month. Canadian PM: discontinue at least 1 month before a planned pregnancy | ~5 days | ~25 days |
| Zepbound | tirzepatide | Discontinue when pregnancy is recognized; no numeric preconception window | Canadian PM: discontinue at least 1 month before a planned pregnancy | ~5 days | ~25 days |
| Saxenda | liraglutide (weight loss) | Weight loss offers no benefit in pregnancy and may cause fetal harm; discontinue when pregnancy is recognized | UK MHRA: 0 months after stopping | ~13 hours | ~3 days |
| Victoza | liraglutide (Type 2 diabetes) | Use only if benefit justifies risk; discontinue when pregnancy is recognized | UK MHRA: 0 months after stopping | ~13 hours | ~3 days |
| Trulicity | dulaglutide | Use only if benefit justifies risk; no numeric preconception window | Canadian PM: discontinue at least 1 month before a planned pregnancy | ~5 days | ~25 days |
| Foundayo | orforglipron (oral) | Discontinue when pregnancy is recognized; no numeric preconception window | New drug (FDA-approved April 2026) — limited ex-US guidance | 29–49 hours | ~6–10 days |
| Bydureon BCise | exenatide ER | Use only if clearly needed; verify current label | UK FSRH/CoSRH: about 12 weeks before planned pregnancy | Long (extended-release matrix) | Several weeks |
The "US FDA label" column is what the prescribing information actually says about preconception timing — that's the strongest source. When the US label is silent on a numeric window (tirzepatide, dulaglutide, orforglipron), the "Ex-US regulator window" column fills the gap with UK MHRA guidance or the Canadian product monograph. Half-life and 5-half-life columns are pharmacokinetic math from the label's Clinical Pharmacology section — useful as a floor, not a ceiling.
Semaglutide (Wegovy, Wegovy HD, Wegovy tablets, Ozempic, Rybelsus) — stop at least 2 months before
This is the cleanest rule in the whole class. Every semaglutide label says the same thing: discontinue at least 2 months before a planned pregnancy due to the long washout period. That applies to Wegovy injection, Wegovy HD (the 7.2 mg dose approved in March 2026), Wegovy tablets, Ozempic, and Rybelsus.
The label reason is the long half-life. Semaglutide's half-life is about 7 days, so 5 half-lives (the standard pharmacokinetic clearance benchmark) is around 35 days. The label adds extra margin on top of that.
If you've heard "5 weeks is enough because the half-life math says so" — the manufacturer and the FDA disagree. Follow the label.
Tirzepatide (Mounjaro, Zepbound) — the answer your doctor and the internet disagree about
This one's messier. The US Mounjaro and Zepbound labels do not give you a number for preconception planning. They say "discontinue when pregnancy is recognized" — which doesn't help you plan ahead.
The verified numeric minimums come from outside the US. Both the UK MHRA and the Canadian product monograph from Eli Lilly say to stop tirzepatide at least 1 month before a planned pregnancy because of the long half-life.
Editorial planning default: if your US clinician hasn't given you a tirzepatide stop date, use the verified 1-month UK/Canada minimum as the floor, then ask whether your specific fertility clinic or prescriber wants a longer buffer before TTC, IUI, or embryo transfer. Some clinics will. Some won't. That's clinic-specific — not a universal rule we can confirm.
Tirzepatide has a second clock you can't skip — the birth control clock. It runs separately from the pregnancy clock and trips up a lot of people. The full breakdown is in the contraception section below.
Liraglutide (Saxenda, Victoza) — short half-life, fastest washout
Liraglutide is the outlier in the class. Half-life is 13 hours. The drug is ~99% gone in about 3 days. UK MHRA washout guidance for liraglutide is literally "0 months after stopping."
- Saxenda (the 3.0 mg weight-loss dose): the label says weight loss offers no benefit in pregnancy and may cause fetal harm. Discontinue when pregnancy is recognized.
- Victoza (up to 1.8 mg, for Type 2 diabetes): the label uses the standard diabetes phrasing — use only if the potential benefit justifies the risk. Don't stop without a glucose bridge plan.
Practically, liraglutide has the shortest preconception window of any GLP‑1 — which is why some prescribers switch patients from semaglutide or tirzepatide to liraglutide a few months before TTC when the pregnancy timeline is tight. Whether that switch makes sense in your case is a prescriber decision.
Dulaglutide (Trulicity) — diabetes-focused, often missed
Trulicity gets less attention in fertility content because it's almost always prescribed for Type 2 diabetes, not weight loss. The US label says use only if benefit justifies risk and doesn't include a numeric preconception window.
The Canadian product monograph from Eli Lilly fills the gap: discontinue Trulicity at least 1 month before a planned pregnancy due to the long washout period. Half-life is ~5 days, similar to tirzepatide.
If you're on Trulicity for diabetes, the more urgent conversation is what to switch to during pregnancy planning — usually insulin or metformin. Don't stop the GLP‑1 without that bridge in place.
Foundayo (orforglipron) — the new oral GLP‑1 (FDA-approved April 2026)
This one's new enough that most other guides don't cover it yet. The FDA approved Foundayo on April 1, 2026 — it's the first oral non-peptide GLP‑1, made by Eli Lilly, taken once daily with no food restrictions.
- The label does not give a numeric preconception washout window. It says discontinue when pregnancy is recognized. By pharmacokinetic math (29–49 hour half-life, 5 half-lives ≈ 6–10 days), the drug is largely cleared within about a week and a half. That's the math — it isn't a proven TTC safety window. Confirm the stop date with your prescriber.
- The contraception rule is its own thing. The label says use non-oral birth control or add a barrier method for 30 days after starting and 30 days after each dose increase, because Foundayo may reduce oral hormonal contraceptive efficacy. The label specifically notes the effect on oral contraceptive absorption has not been evaluated in a clinical trial — this is a precaution based on the drug class, not a measured PK reduction.
Because Foundayo is new, expect both the label and clinical practice to evolve over the next 12–24 months.
Compounded semaglutide and tirzepatide — verify what you actually have
If you're using a compounded GLP‑1, the active molecule determines your washout — but you need to verify what's actually in the vial first.
- Compounded GLP‑1s are not FDA-approved in the same way Wegovy or Zepbound are. They don't have their own prescribing information.
- The FDA has warned about compounded GLP‑1 products that contain salt forms — semaglutide sodium or semaglutide acetate — which are different molecules than the approved base form. The agency has also flagged dosing errors, hospitalizations, and fraudulent products.
- If the product is truly semaglutide or tirzepatide, the conservative washout logic above applies. But you cannot assume the vial matches the brand drug.
Before pregnancy planning, bring the actual bottle, lot number, and pharmacy info to your OB-GYN or prescriber. Verify the exact active ingredient, form, and dose. If you can't verify what you've been taking, treat that as its own conversation — the answer is not "assume it's the same as Wegovy."
Why the washout numbers disagree (and which one to follow)
Answer capsule
Patients get different washout timelines from their OB-GYN, their endocrinologist, their fertility clinic, and the internet because the US FDA label, the UK MHRA guidance, the Canadian product monograph, and pharmacokinetic math all give different numbers. The pharmacokinetic floor (5 half-lives) is the earliest the drug is essentially gone. The FDA label adds a margin on top. Fertility clinics often add even more for caution. Your prescriber's specific number overrides everything else — but if no one has given you one, follow the FDA label window for your specific drug.
Table 2: Stated vs. verified — where each washout number comes from
| Source you've heard from | What they typically say | Where the number comes from | When to follow it |
|---|---|---|---|
| US FDA label (semaglutide) | "2 months before planned pregnancy" | Manufacturer pharmacokinetic data submitted to FDA | Default for any semaglutide product. The strongest source. |
| US FDA label (tirzepatide) | "Discontinue when pregnancy recognized" — no preconception window | US Zepbound / Mounjaro prescribing information | Technically the only US requirement, but not helpful for planning. Use ex-US guidance below. |
| UK MHRA washout table | Semaglutide: 2 months. Tirzepatide: 1 month. Liraglutide: 0 months. Exenatide ER: ~12 weeks (FSRH/CoSRH). | UK regulator's public preconception guidance | Reliable when the US label is silent. |
| Canadian product monograph | Tirzepatide and Trulicity: at least 1 month before planned pregnancy. Semaglutide: 2 months. | Eli Lilly and Novo Nordisk's Canadian PMs | Strongest manufacturer source when the US label is silent. |
| 5 half-lives math | Sema: ~35 days. Tirz: ~25 days. Liraglutide: ~3 days. Foundayo: ~6–10 days. | Clinical Pharmacology section of each label | Minimum floor only — not the same as the label-recommended stop date. |
| Reproductive endocrinologist (RE) | Often 2–3 months for any GLP-1; sometimes longer for IVF | Conservative clinical extrapolation, accounting for IVF cycle timing and clinic risk policy | Follow your RE's specific number — they're responsible for your cycle outcome. |
| Anesthesiologist | Older ASA 2023 guidance: hold weekly GLP-1 ≥7 days before sedation. 2024 multi-society guidance: most patients can continue with precautions. | ASA 2023 vs. 2024 multi-society perioperative guidance | For procedures (egg retrieval, surgery), not conception. Different question. |
What to do if you're already pregnant on a GLP‑1
Answer capsule
If you get a positive pregnancy test while still on a GLP‑1, do not take another dose, and contact your prescriber and OB-GYN the same day. If you take the GLP‑1 for Type 2 diabetes, don't stop or change anything else in your glucose plan on your own — ask what to switch to. Current outcome studies are reassuring but still limited. Enroll in the manufacturer's pregnancy exposure registry if one is available.
Immediate steps
- Do not take your next dose.
- Call your prescriber and OB-GYN the same day — not tomorrow, not at your next scheduled appointment.
- Write down the exact drug name, dose, and date of your most recent injection or pill before you make the call.
- If you're on a GLP‑1 for Type 2 diabetes: do not adjust insulin, metformin, or any other glucose medication on your own. Your endocrinologist drives this transition, not your OB-GYN.
- Ask specifically about enrollment in the manufacturer's pregnancy exposure registry for your drug. For Wegovy, Mounjaro, Zepbound, and Foundayo, current product labels include a registry number — ask your prescriber to confirm the current number at your appointment.
What the current outcome data actually shows
The current evidence is observational and limited. The major studies:
- Dao K et al., BMJ Open 2024 — 168 first-trimester GLP‑1 RA exposures: no significant increase in major congenital malformations vs. disease-matched controls.
- Kolding et al., Basic & Clinical Pharmacology & Toxicology 2025 — 32 first-trimester semaglutide exposures (Danish national cohort): no significant malformation signal.
- Mandal et al., European Journal of Obstetrics & Gynecology and Reproductive Biology (systematic review) — Pooled review of 1,128 semaglutide-exposed pregnancies across 5 studies. Conclusion: "No consistent link found between semaglutide use and major congenital malformations."
Honest summary: the signal for major birth defects isn't there yet in observational data. But "no signal yet" is not the same as "proven safe" — that's why prescribers still want you to stop, and why registries matter. Reassuring is reassuring. It isn't permission.
The diabetes transition
If you're on a GLP‑1 for Type 2 diabetes, call your prescriber the same day. They'll typically transition you to insulin or metformin, both of which are well-established in pregnancy. Don't wait until your next regular appointment.
- Insulin — the gold standard for pregnancy. Doesn't cross the placenta. Decades of safety data.
- Metformin — also used in pregnancy, particularly for PCOS-related insulin resistance.
GLP‑1s and IVF: different timelines for retrieval vs. transfer
Answer capsule
IVF involves two separate decisions about your GLP‑1, not one. Egg retrieval is a sedation question — older ASA 2023 guidance recommended holding weekly GLP‑1 injections at least 7 days before a procedure under sedation, while the 2024 multi-society perioperative guidance softens that to "most patients can continue with precautions." Fertility clinics often still use the more conservative 7-day hold. Embryo transfer is a pregnancy attempt — plan it using the full preconception washout for your specific drug.
Table 3: GLP‑1 timing across IVF steps
| Fertility step | Action on your GLP‑1 | Why |
|---|---|---|
| Preconception consultation, genetic testing | Usually continue | No anesthesia, no conception attempt |
| Start of ovarian stimulation injections | Many clinics begin reducing or holding here | Reduces aspiration risk for retrieval and starts the washout if a transfer is planned |
| Egg retrieval (under sedation) | Hold per your clinic's policy; common policies include holding weekly GLP-1 ≥7 days before and daily GLP-1 the day of | Delayed gastric emptying → aspiration risk under anesthesia |
| Egg freezing only (no transfer planned) | Restart timing is set by the fertility clinic and prescriber after retrieval | No pregnancy is being attempted, so the full preconception washout may not be required |
| Fresh embryo transfer | Stop ≥2 months before (semaglutide) or ≥1 month before (tirzepatide/dulaglutide, per ex-US labels) | The transfer is a pregnancy attempt; full preconception washout applies |
| Frozen embryo transfer (FET) | Same as fresh transfer — full preconception washout | Pregnancy can establish within days of transfer |
| IUI or timed intercourse | Same as natural-cycle TTC | Treat like a pregnancy attempt date |
Egg retrieval has its own clock — and it's about anesthesia, not the fetus
GLP‑1s slow how fast food leaves the stomach. When you're going under sedation for egg retrieval, a partially-full stomach raises the risk of aspiration.
- Older ASA 2023 guidance recommended holding weekly GLP‑1 injections for at least 7 days before any procedure under sedation, and holding daily GLP‑1s the day of.
- 2024 multi-society perioperative guidance softens this — most patients can continue with enhanced precautions (solid food restriction, ultrasound assessment, aspiration protocols). Verify your specific clinic's current policy.
Useful questions to ask your fertility team: "Does your protocol require stopping before stimulation, retrieval, or only transfer?" — "What's the exact last-dose deadline for my specific medication?" — "Does your policy differ for semaglutide vs. tirzepatide?"
Fresh transfer vs. frozen embryo transfer — both need the full washout
Whether the transfer is fresh (days after retrieval) or frozen (weeks or months later), the rule is the same: the transfer date is the conception date. Apply the full preconception washout for your specific drug, counted backward from the transfer date.
Your fertility team may use a slightly different number than the FDA label — follow their protocol. They're accountable for your cycle outcome.
GLP‑1s and birth control during the washout window
Answer capsule
Most GLP‑1s do not reduce the effectiveness of birth control pills. The clear exception is tirzepatide (Mounjaro, Zepbound), which reduces oral contraceptive exposure by about 20% — switch to a non-oral method or add a barrier method for 4 weeks after starting and 4 weeks after each dose increase. Foundayo (orforglipron) has a label-based precaution for 30 days after starting and 30 days after each dose increase, though the FDA notes the effect hasn't been measured in a clinical trial. Severe vomiting on any GLP‑1 can also affect oral pill absorption.
Tirzepatide has two clocks. Don't confuse them.
This is the single most under-discussed safety issue in the entire GLP‑1 class:
- Pregnancy washout clock: how long after your last dose until it's safe to try to conceive. (1 month per UK MHRA and Canadian PM.)
- Birth control backup clock: how long after starting tirzepatide — or after each dose increase — your oral birth control pill may be less effective. (4 weeks per the US Mounjaro / Zepbound label.)
These windows can overlap, but they answer different questions. If you increase your dose next month, the 4-week clock resets. If you decide to try to conceive, that's a separate washout window starting from your last dose.
Table 4: GLP‑1 effect on hormonal birth control
| Drug | Reduces oral pill effectiveness? | What the label says |
|---|---|---|
| Mounjaro / Zepbound (tirzepatide) | Yes — measured ~20% reduction | Switch to a non-oral method OR add a barrier method for 4 weeks after starting and 4 weeks after each dose increase |
| Foundayo (orforglipron) | Label-based precaution — effect not measured in a clinical trial | Use a non-oral method (IUD, ring, implant) OR add a barrier method for 30 days after starting and 30 days after each dose increase |
| Wegovy / Wegovy HD / Wegovy tablets / Ozempic / Rybelsus (semaglutide) | No clinically meaningful reduction | Standard contraception is fine |
| Saxenda / Victoza (liraglutide) | No | Standard contraception |
| Trulicity (dulaglutide) | No | Standard contraception |
Important: vomiting still matters
Even when the drug itself doesn't reduce contraceptive levels, severe vomiting from any GLP‑1 — especially in the first month or after a dose increase — can affect oral pill absorption. UK FSRH guidance: if vomiting happens within a few hours of taking an oral contraceptive pill, follow your pill's missed-pill instructions. If vomiting or severe diarrhea persists more than 24 hours, ask about non-oral or backup contraception.
Non-oral contraception options that bypass the issue
If you're on tirzepatide or Foundayo and don't want to manage backup methods every dose increase, switching to a non-oral method removes the issue entirely:
- IUD (copper or hormonal) — among the most effective methods available, lasts 3–12 years depending on type
- Implant (Nexplanon) — 3-year duration
- Contraceptive ring (NuvaRing, Annovera) — hormones absorbed vaginally, not affected by gastric emptying
- Contraceptive patch — note: some research suggests reduced effectiveness in people over 198 lbs; confirm with your prescriber
- Depo-Provera injection — quarterly, fully bypasses the GI tract
IUDs and implants are both reversible, both have under-1% typical-use failure rates, and neither depends on stomach absorption.
Will I gain the weight back during the washout? And does that hurt my fertility?
Answer capsule
Some weight regain after stopping a GLP‑1 is common because appetite suppression ends. For most patients, a modest 4–8 week washout doesn't erase the fertility benefit of the weight you lost. However, a 2025 JAMA cohort study found that women who discontinued GLP‑1s before or in early pregnancy gained on average 7.2 lbs more during pregnancy and had higher rates of excess gestational weight gain, gestational diabetes, hypertensive disorders, and preterm delivery compared to women with obesity who hadn't used a GLP‑1. That's not a reason to skip the washout — you can't safely continue the GLP‑1. It's a reason to plan the washout window actively, not passively.
What the JAMA 2025 cohort actually found
The 2025 study examined women with obesity who used a GLP‑1 and discontinued before or during early pregnancy. Compared to women with obesity who didn't use a GLP‑1, the discontinuation group:
- Gained about 7.2 lbs more gestational weight on average
- Had higher rates of excess gestational weight gain
- Had higher rates of gestational diabetes
- Had higher rates of hypertensive disorders of pregnancy
- Had higher rates of preterm delivery
The data is observational, so it can't prove cause and effect — but it tells you that the post-stop period deserves a structured plan, not passive waiting.
What to expect physically in the first 4 weeks off
- Appetite returning within 7–14 days (food noise comes back)
- Mild fluid shifts as the drug clears
- Stronger hunger cues, especially before meals
- Slower fullness signals at meals
- Cravings that were suppressed may return
What's usually not happening: rapid uncontrolled weight regain in the first month. That tends to come later — around 8–12 weeks off — if no replacement strategy is in place.
A practical preconception plan during washout
- Protein floor. Aim for at least 0.6–0.8 grams of protein per pound of goal body weight per day. Protein blunts appetite and preserves lean mass.
- Daily walking. 20–40 minutes most days — for appetite regulation and insulin sensitivity, not calorie burn.
- Sleep priority. Under-sleeping is one of the fastest paths to weight regain. Protect 7+ hours.
- PCOS users: consider a metformin bridge. Metformin is commonly continued through the washout window and into pregnancy for women with PCOS-related insulin resistance — it's one of the most data-backed interventions in this population. This is a prescriber decision based on your labs and history.
Breastfeeding and restarting after delivery
| Drug | Breastfeeding label summary |
|---|---|
| Wegovy / Wegovy HD injection (semaglutide) | A clinical lactation study reported semaglutide concentrations below the lower limit of quantification in human breast milk; an absorption enhancer used in oral semaglutide (SNAC) is present in human milk. Label says to weigh maternal need against infant exposure. |
| Wegovy tablets / Rybelsus (oral semaglutide) | Breastfeeding not recommended during oral semaglutide treatment due to SNAC. |
| Ozempic (semaglutide) | Limited human data; weigh risks framing. |
| Mounjaro / Zepbound (tirzepatide) | A small lactation study showed low or undetectable tirzepatide concentrations in milk; no infant outcome data. Most prescribers still recommend pausing while breastfeeding. |
| Foundayo (orforglipron) | Not recommended for nursing women, per the current label. |
| Saxenda / Victoza (liraglutide) | Limited human data. |
| Trulicity (dulaglutide) | Limited human data. |
If you plan to breastfeed for 6+ months before restarting, factor that into your overall pregnancy spacing plan, especially if you want to use a GLP‑1 for postpartum weight loss before a second pregnancy.
Are "Ozempic babies" real?
Yes — surprise pregnancies on GLP‑1 medications happen, and there are real mechanisms behind them. GLP‑1s restore ovulation in many women with PCOS or obesity-related anovulation. Tirzepatide specifically reduces oral contraceptive absorption. And cycles that were irregular for years can normalize on a GLP‑1, which means people whose contraception planning was loose may underestimate their pregnancy risk. GLP‑1s are not fertility drugs, but they can create the metabolic conditions for conception in patients who weren't ovulating before. Use reliable contraception while on these drugs unless you're actively trying.
6 questions to bring to your prescriber appointment
If you walk out of the appointment without answers to all six, you didn't get what you came for.
- 1Based on my specific drug and dose, what is the earliest date I can start trying to conceive?
- 2What contraception do I use until then — and does it need to change because of my GLP-1?
- 3If I'm doing IVF, when do I stop relative to stimulation, retrieval, and transfer?
- 4What do I bridge to for my PCOS / Type 2 diabetes / weight maintenance during the washout?
- 5What's the plan if I miss the timing and find out I'm pregnant earlier than expected?
- 6When can I restart after delivery — and does the answer change if I'm breastfeeding?
Related guides on GLP‑1 safety and comparison
Frequently asked questions
How long after stopping Ozempic can I get pregnant?
At least 2 months. The US FDA Ozempic label specifically states "discontinue at least 2 months before a planned pregnancy due to the long washout period." Semaglutide's half-life is about 7 days.
How long do I need to be off Wegovy before trying to conceive?
At least 2 months. Same rule as Ozempic — they're both semaglutide. This applies to Wegovy injection, Wegovy HD, Wegovy tablets, Ozempic, and Rybelsus.
How long after stopping Mounjaro or Zepbound can I get pregnant?
The UK MHRA and the Canadian Eli Lilly product monograph both say at least 1 month. The US Mounjaro and Zepbound labels don't give a specific preconception number — they say to discontinue when pregnancy is recognized. Use 1 month as your verified floor, and confirm with your prescriber.
Is it safe to get pregnant on a GLP-1?
GLP-1 medications are not recommended during pregnancy. The largest current outcome studies (including a 2024 multicenter European cohort of 168 first-trimester GLP-1 exposures and a 2025/2026 systematic review of 1,128 semaglutide-exposed pregnancies) haven't shown a clear increase in major birth defects, but the evidence is still observational and limited. If you find out you're pregnant on a GLP-1, don't take another dose, and contact your prescriber the same day.
Does Wegovy affect birth control pills?
Semaglutide products including Wegovy do not significantly reduce oral contraceptive absorption based on clinical pharmacology studies in the label. However, severe vomiting on any GLP-1 can affect oral pill absorption — follow your pill's missed-pill instructions if vomiting occurs within a few hours of taking it.
Does Mounjaro affect birth control pills?
Yes. Tirzepatide (Mounjaro and Zepbound) reduces oral contraceptive exposure by about 20%. The US label instructs patients to switch to a non-oral method or add a barrier method for 4 weeks after starting and 4 weeks after each dose increase.
Does Foundayo (orforglipron) affect birth control?
The FDA label says Foundayo may reduce oral hormonal contraceptive efficacy, though it notes the effect on oral contraceptive absorption has not been evaluated in a clinical trial. The label-based precaution: use a non-oral method or add a barrier method for 30 days after starting and 30 days after each dose increase.
Can I do IVF while on a GLP-1?
You can do the early stages — consultation, genetic testing, evaluation. You need to pause the GLP-1 around egg retrieval per your fertility clinic's policy (most still use a 7-day hold for weekly injections to manage anesthesia aspiration risk, though 2024 multi-society perioperative guidance is more permissive). For embryo transfer, plan the full preconception washout for your drug — the transfer is the conception attempt.
Can I keep using a GLP-1 if I'm doing egg freezing but not a transfer?
Usually yes, with a short pause around the retrieval procedure. The restart date comes from your fertility clinic and prescriber. Since no pregnancy is established from egg freezing alone, the full preconception washout isn't required.
What if I took a dose during the washout window by mistake?
Don't guess at the timeline. Reset your "last dose" date and recalculate from there. Bring the exact date and dose to your prescriber. For semaglutide, the 2-month clock restarts from the new last-dose date.
Are compounded semaglutide or tirzepatide safer for pregnancy planning?
No — and you can't assume they're equivalent to the brand drug. Compounded GLP-1s are not FDA-approved, and some have contained salt forms (semaglutide sodium, semaglutide acetate) that are different molecules than the approved drug. The FDA has issued safety warnings about dosing errors, hospitalizations, and fraudulent compounded GLP-1 products. Before pregnancy, verify the exact active ingredient, dose, and pharmacy with your prescriber.
Can my male partner stay on his GLP-1 while we try to conceive?
There's no FDA label washout rule for a male partner trying to conceive while on a GLP-1. The data on male exposure is thinner than for maternal exposure, so this is a prescriber conversation — not a mandatory page-level delay.
Do GLP-1s improve fertility?
Indirectly, for some patients. Weight loss and improved insulin sensitivity can restore ovulation in women with PCOS or obesity-related anovulation. A 2018 pilot randomized study of liraglutide plus metformin before IVF showed higher pregnancy rates in obese PCOS women than metformin alone. GLP-1s are not FDA-approved fertility drugs, but they can create metabolic conditions that support conception.
How long does it take to ovulate again after stopping a GLP-1?
It varies. Patients who were already ovulating regularly usually don't notice a change. Patients with PCOS or obesity-related anovulation may notice cycle changes within 1–3 months after stopping, as weight stabilizes or rises. Track your cycles starting the day you stop.
Can I take a GLP-1 while breastfeeding?
Most GLP-1 labels recommend against breastfeeding use or have limited data. Oral semaglutide products (Rybelsus, Wegovy tablets) have the strongest warning due to the absorption enhancer SNAC. Foundayo's label specifically says not recommended for nursing women. Injectable semaglutide, tirzepatide, liraglutide, and dulaglutide all have limited human milk data — most prescribers wait until after weaning to restart.
Will I gain all the weight back during the 2-month washout?
Some regain is common but usually modest in the first 4–8 weeks. A 2025 JAMA cohort study found women who stopped GLP-1s near pregnancy gained about 7.2 lbs more gestational weight on average and had higher rates of gestational diabetes, hypertensive disorders, and preterm delivery than women with obesity who hadn't used a GLP-1. That's a reason to plan the washout window actively — protein, walking, sleep, and (for PCOS) a metformin bridge are the most common tools.
Are "Ozempic babies" real?
Yes — surprise pregnancies on GLP-1 medications happen, and there are real mechanisms behind them. GLP-1s restore ovulation in many women with PCOS or obesity-related anovulation. Tirzepatide specifically reduces oral contraceptive absorption. And cycles that were irregular for years can normalize on a GLP-1, which means people whose contraception planning was loose may underestimate their pregnancy risk. GLP-1s are not fertility drugs, but they can create the metabolic conditions for conception in patients who weren't ovulating before.
What we actually verified for this guide
We pulled the current FDA Highlights of Prescribing Information for the drugs on this page directly from accessdata.fda.gov (and the manufacturer mirrors at pi.lilly.com/us and novo-pi.com) on May 15, 2026. Where the US label is silent on preconception timing, we cross-checked the Canadian product monograph and UK MHRA public guidance.
Specifically verified:
- ✅ Wegovy / Wegovy HD / Wegovy tablets (semaglutide) FDA label — 2-month preconception rule
- ✅ Ozempic (semaglutide) FDA label — 2-month preconception rule
- ✅ Rybelsus (oral semaglutide) FDA label — 2-month preconception rule
- ✅ Mounjaro (tirzepatide) FDA label and Eli Lilly Canadian PM — Canadian PM specifies at least 1 month before planned pregnancy
- ✅ Zepbound (tirzepatide) FDA label — discontinue when pregnancy recognized; Canadian PM: 1 month
- ✅ Saxenda (liraglutide) FDA label — discontinue when pregnancy recognized
- ✅ Victoza (liraglutide) FDA label — use only if benefit justifies risk
- ✅ Trulicity (dulaglutide) FDA label — use only if benefit justifies risk; Canadian PM: 1 month before planned pregnancy
- ✅ Foundayo (orforglipron) FDA label — 29–49 hour half-life; 30-day contraception backup during titration
- ✅ US tirzepatide oral contraceptive label language — 4 weeks after start and each dose increase
- ✅ UK MHRA preconception washout table and FSRH/CoSRH contraception guidance — including 12-week exenatide washout
- ✅ ASA 2023 perioperative GLP-1 guidance and 2024 multi-society perioperative update
Pregnancy outcome studies cited:
- Dao K et al., BMJ Open 2024 — 168 first-trimester GLP-1 RA exposures
- Kolding et al., Basic & Clinical Pharmacology & Toxicology 2025 — 32 first-trimester semaglutide exposures (Danish national cohort)
- Morton A & He J, Obstetric Medicine 2025 — 13 first-trimester semaglutide exposures
- Mandal et al., European Journal of Obstetrics & Gynecology and Reproductive Biology systematic review — 1,128 pooled semaglutide-exposed pregnancies across 5 studies
- 2025 JAMA cohort study on GLP-1 discontinuation and gestational weight gain / GDM / hypertensive disorders / preterm delivery
What we did not verify and won't claim as fact:
- Your specific fertility clinic's exact stop policy (clinics vary; ask yours)
- Your individual pregnancy risk
- Long-term developmental outcomes in children exposed in utero (data doesn't exist yet at scale)
- Pregnancy exposure registry programs for Ozempic, Rybelsus, Saxenda, Victoza, and Trulicity at this revision — ask your prescriber whether one is currently available for your product
This is an educational resource, not medical advice. The right washout window for your situation is the one your prescriber gives you, based on your specific drug, dose, medical history, and pregnancy plan. If your prescriber gives you a number different from what's on this page, follow theirs.
Disclosure
By the WPG Research Team · Last verified: May 15, 2026 · Next scheduled review: August 2026
Have a correction or a new study we should add? We update this page when the evidence changes, not on a marketing schedule. Contact us →
Foundayo™ is a trademark of Eli Lilly and Company. Wegovy®, Ozempic®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Zepbound®, KwikPen®, Mounjaro®, Trulicity®, and Bydureon® are registered trademarks of Eli Lilly and Company. Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S. Weight Loss Provider Guide is not affiliated with or endorsed by Eli Lilly and Company or Novo Nordisk A/S.